Pranshu MohindraUniversity Of Maryland Medical Center

    Dr. Mohindra’s prior training experience includes two radiation oncology residencies (Tata Memorial Centre, Mumbai and University of Wisconsin, Madison), Head-Neck cancer clinical fellowship (Princess Margaret Hospital, University of Toronto) and a post-doctoral Global Academic Research Associate at the U. T. MD Anderson Cancer Center; Houston. He has received several academic excellence, research and travel awards during his residency including the 2014 Radiological Society of North America (RSNA) Roentgen Resident/Fellow Award for outstanding radiologic research and the 2014 American Society for Radiation Oncology (ASTRO) Resident Digital Poster Discussion Award in the Biology category. He also served as the Chief resident, Radiation Oncology, University of Wisconsin, Madison, for the year 2013-14.

    Dr. Mohindra joined the Department of Radiation Oncology at the University of Maryland School of Medicine, Baltimore in July 2014 as an Assistant Professor in a clinician-scientist role. His primary area of clinical and research interest is in thoracic/lung, gynecological and hemato-lymphoid malignancies. Dr. Mohinda played a key role in the initiation of the department’s MRI-guided brachytheapy program for women with cervical cancer. He has helped establish UMMC as a referral center for complex high dose rate (HDR) tandem-ring brachytherapy and interstitial brachytherapy for gynecological cancers. Dr. Mohindra is amongst the select providers in the entire Maryland-DC region who has the expertise in performing these brachytherapy procedures. He is also credited with Maryland State’s first Cardiac Radioablation case in collaboration with UMMC EP team. He is currently working on expanding the use of modern technologies like proton beam therapy for the management of thoracic/lung, gynecological and hemato-lymphoid malignancies.

    While continuing to build novel clinical programs and providing expert radiation oncology service, one of his key goals is to represent UMSOM nationally through cutting-edge research. His research efforts include evaluating treatment outcomes through institutional and population-based databases, development of early phase clinical trials evaluating both radiation sensitizers and radiation toxicity mitigators or evaluation of modern radiation techniques including proton beam therapy. He has active involvement in multi-disciplinary collaborative research endeavors including prospective clinical protocols with special emphasis on early phase clinical trials evaluating both radiation sensitizers and radiation toxicity mitigators or evaluation of modern radiation techniques. He is the national PI of two NCI-sponsored phase-I clinical trials; one evaluating VX-970, a novel DNA repair pathway inhibitor with whole brain radiotherapy (WBRT) in patients with brain metastases from NSCLC (CIRB and CTEP approved, NCT02589522, career development project team award) and another evaluating the combination of oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) with WBRT in brain metastases (CIRB and CTEP approved, NCT02993146). He is the Radiation Oncology Co-chair for the Alliance for Clinical Trials in Oncology A041501A study: Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL and Alliance Champion for the NRG-sponsored national study: LU002 Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial.

    Dr. Mohindra represents UMGCCC as the nominated member to the Board of Directors for the Alliance for Clinical Trials in Oncology which comprises nearly 10,000 cancer specialists at hospitals, medical centers, and community clinics across the United States and Canada. He holds committee appointments within Alliance (Radiation Oncology, Respiratory, Symptom Intervention and Cancer in the Older Adults) and American Society for Radiation Oncology (Workforce and Research Grants Evaluation Subcommittee). He has served as member of the Advanced Radiation Technology Committee, International Association for the Study of Lung Cancer (IASLC) and is a current member of the Education Committee of IASLC. He is an appointed member of the ACR Radiation Oncology In-Training (TXITTM) Exam committee (Thoracic: 2015-2016 and Gynecology, Lymphoma: 2016) developing examination questions for residents in radiation oncology. Since 2017, he took over as the section chair for Thoracic section of the examination.

    Within the Department of Radiation Oncology, UMB, Dr. Mohindra is appointed as Director of Research Internships and oversee the activities of all research-related internships that span more than 30 days. Through 2017 and 2018, this program has awarded $20,000 in awards to five UMSOM medical students for summer fellowships, two medical student research scholarship award and one medical student graduation research award. He has personally mentored medical students and residents on research projects that have led to national awards: Applied Radiation Oncology Clinical Case Contest Winner (Stephanie Rice, MS-4, Univ. Wisconsin, 2014), Medical Student Award for 2017 Alpha Omega Alpha Carolyn Kuckein Fellowship Competition (Jiun Yiing Hu, MS-1, UMSOM, 2017) and Radiation Oncology Institute Excellence Award for a research manuscript (Melissa Vyfhuis, Chief Resident Radiation Oncology, UMSOM, 2017). He is also the Lead, Scope of Practice, Policy and Procedure Management Workgroup of Quality and Safety Review Council. In this role, he will oversee development of SOPs for various departmental clinical activities and establish uniform procedures system-wise.